# A Study of QL1706 in Combination With Chemotherapy in PD-L1-Negative Non-small Cell Lung Cancer

Source: https://onco.cc/trials/nct05690945/  
OnCo record `nct05690945` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing QL1706 in non-small-cell lung cancer, active and no longer recruiting.

## Summary

A Study of QL1706 in Combination With Chemotherapy in PD-L1-Negative Non-small Cell Lung Cancer is a phase 3 interventional study registered as NCT05690945, led by Qilu Pharmaceutical, and active but no longer recruiting on the registry. Official title: A Randomised, Double-blind, Multicenter Phase 3 Clinical Study to Evaluate the Efficacy and Safety of QL1706 in Combination With Chemotherapy in First-line PD-L1 Negative, Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients. Planned enrolment is 606 participants (actual). The study started in 2023-02-15 and primary completion is expected in 2029-06. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT05690945
- Phase: 3
- Setting: A Randomized, Double-blind, Multicenter Phase 3 Clinical Study to Evaluate the Efficacy and Safety of QL1706 in Combination With Chemotherapy in First-line PD-L1 Negative, Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients
- Sponsor: Qilu Pharmaceutical
- Enrolled: 606

## Sources

- ClinicalTrials.gov NCT05690945: https://clinicaltrials.gov/study/NCT05690945

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [QL1706](https://onco.cc/drugs/ql1706/)
- companies: [Qilu Pharmaceutical](https://onco.cc/companies/qilu-pharmaceutical/)

---
JSON: https://onco.cc/api/v1/entities/nct05690945.json